1.42 USD
+0.01 (+0.71%)
1.42 USD
0 (0%)
Taking everything into account, CHRS scores 2 out of 10 in our fundamental rating. CHRS was compared to 530 industry peers in the Biotechnology industry. CHRS has a bad profitability rating. Also its financial health evaluation is rather negative. CHRS has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
CHRS had negative earnings in the past year.
CHRS had a negative operating cash flow in the past year.
In multiple years CHRS reported negative net income over the last 5 years.
CHRS had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
CHRS's Return On Assets of 30.00% is amongst the best of the industry. CHRS outperforms 98.11% of its industry peers.
With an excellent Return On Equity value of 176.56%, CHRS belongs to the best of the industry, outperforming 99.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30% | ||
| ROE | 176.56% | ||
| ROIC | N/A |
ROA(3y)-30.71%
ROA(5y)-23.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CHRS has a Profit Margin of 185.44%. This is amongst the best in the industry. CHRS outperforms 98.87% of its industry peers.
CHRS's Profit Margin has declined in the last couple of years.
With a decent Gross Margin value of 47.79%, CHRS is doing good in the industry, outperforming 75.09% of the companies in the same industry.
In the last couple of years the Gross Margin of CHRS has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 185.44% | ||
| GM | 47.79% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-15.79%
GM growth 3Y-12.08%
GM growth 5Y-10.08%
2. Health
2.1 Basic Checks
CHRS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CHRS has been increased compared to 1 year ago.
CHRS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for CHRS has been reduced compared to a year ago.
2.2 Solvency
CHRS has an Altman-Z score of -4.13. This is a bad value and indicates that CHRS is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of CHRS (-4.13) is comparable to the rest of the industry.
CHRS has a Debt/Equity ratio of 0.58. This is a neutral value indicating CHRS is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.58, CHRS is doing worse than 72.26% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.58 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.13 |
ROIC/WACCN/A
WACC8.47%
2.3 Liquidity
CHRS has a Current Ratio of 1.24. This is a normal value and indicates that CHRS is financially healthy and should not expect problems in meeting its short term obligations.
CHRS has a worse Current ratio (1.24) than 85.28% of its industry peers.
A Quick Ratio of 1.23 indicates that CHRS should not have too much problems paying its short term obligations.
CHRS's Quick ratio of 1.23 is on the low side compared to the rest of the industry. CHRS is outperformed by 84.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.24 | ||
| Quick Ratio | 1.23 |
3. Growth
3.1 Past
CHRS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -19.27%.
The earnings per share for CHRS have been decreasing by -27.39% on average. This is quite bad
The Revenue for CHRS has decreased by -72.54% in the past year. This is quite bad
CHRS shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -5.60% yearly.
EPS 1Y (TTM)-19.27%
EPS 3YN/A
EPS 5Y-27.39%
EPS Q2Q%-3200%
Revenue 1Y (TTM)-72.54%
Revenue growth 3Y-6.5%
Revenue growth 5Y-5.6%
Sales Q2Q%-83.65%
3.2 Future
Based on estimates for the next years, CHRS will show a decrease in Earnings Per Share. The EPS will decrease by -4.36% on average per year.
CHRS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.39% yearly.
EPS Next Y-98.56%
EPS Next 2Y-12.58%
EPS Next 3Y-4.33%
EPS Next 5Y-4.36%
Revenue Next Year-83%
Revenue Next 2Y-46.67%
Revenue Next 3Y-27.94%
Revenue Next 5Y0.39%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
CHRS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CHRS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CHRS's earnings are expected to decrease with -4.33% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-12.58%
EPS Next 3Y-4.33%
5. Dividend
5.1 Amount
CHRS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
1.42
+0.01 (+0.71%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners42.25%
Inst Owner Change-6.36%
Ins Owners6.08%
Ins Owner Change0%
Market Cap171.64M
Revenue(TTM)83.57M
Net Income(TTM)154.97M
Analysts81.82
Price Target5.78 (307.04%)
Short Float %29.04%
Short Ratio27.69
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.95%
Min EPS beat(2)-12.36%
Max EPS beat(2)0.45%
EPS beat(4)1
Avg EPS beat(4)-42.18%
Min EPS beat(4)-108.91%
Max EPS beat(4)0.45%
EPS beat(8)3
Avg EPS beat(8)-57.9%
EPS beat(12)6
Avg EPS beat(12)-36.26%
EPS beat(16)8
Avg EPS beat(16)-35.21%
Revenue beat(2)0
Avg Revenue beat(2)-8.12%
Min Revenue beat(2)-15.42%
Max Revenue beat(2)-0.81%
Revenue beat(4)1
Avg Revenue beat(4)-22.58%
Min Revenue beat(4)-86.37%
Max Revenue beat(4)12.3%
Revenue beat(8)3
Avg Revenue beat(8)-10.27%
Revenue beat(12)4
Avg Revenue beat(12)-11.09%
Revenue beat(16)4
Avg Revenue beat(16)-11.88%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-65.48%
EPS NY rev (1m)-19.18%
EPS NY rev (3m)-19.18%
Revenue NQ rev (1m)0.01%
Revenue NQ rev (3m)-9.97%
Revenue NY rev (1m)-5.42%
Revenue NY rev (3m)-5.42%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.05 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.96 | ||
| P/tB | 4.48 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.3
EYN/A
EPS(NY)-0.95
Fwd EYN/A
FCF(TTM)-0.75
FCFYN/A
OCF(TTM)-0.75
OCFYN/A
SpS0.69
BVpS0.73
TBVpS0.32
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30% | ||
| ROE | 176.56% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 185.44% | ||
| GM | 47.79% | ||
| FCFM | N/A |
ROA(3y)-30.71%
ROA(5y)-23.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-15.79%
GM growth 3Y-12.08%
GM growth 5Y-10.08%
F-Score4
Asset Turnover0.16
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.58 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.24 | ||
| Quick Ratio | 1.23 | ||
| Altman-Z | -4.13 |
F-Score4
WACC8.47%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.27%
EPS 3YN/A
EPS 5Y-27.39%
EPS Q2Q%-3200%
EPS Next Y-98.56%
EPS Next 2Y-12.58%
EPS Next 3Y-4.33%
EPS Next 5Y-4.36%
Revenue 1Y (TTM)-72.54%
Revenue growth 3Y-6.5%
Revenue growth 5Y-5.6%
Sales Q2Q%-83.65%
Revenue Next Year-83%
Revenue Next 2Y-46.67%
Revenue Next 3Y-27.94%
Revenue Next 5Y0.39%
EBIT growth 1Y-33.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-87.59%
EBIT Next 3Y12.47%
EBIT Next 5Y7.38%
FCF growth 1Y65.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y65.55%
OCF growth 3YN/A
OCF growth 5YN/A
COHERUS ONCOLOGY INC / CHRS FAQ
What is the ChartMill fundamental rating of COHERUS ONCOLOGY INC (CHRS) stock?
ChartMill assigns a fundamental rating of 2 / 10 to CHRS.
What is the valuation status of COHERUS ONCOLOGY INC (CHRS) stock?
ChartMill assigns a valuation rating of 0 / 10 to COHERUS ONCOLOGY INC (CHRS). This can be considered as Overvalued.
Can you provide the profitability details for COHERUS ONCOLOGY INC?
COHERUS ONCOLOGY INC (CHRS) has a profitability rating of 3 / 10.
What is the expected EPS growth for COHERUS ONCOLOGY INC (CHRS) stock?
The Earnings per Share (EPS) of COHERUS ONCOLOGY INC (CHRS) is expected to decline by -98.56% in the next year.